Connection

Mark Kindy to Humans

This is a "connection" page, showing publications Mark Kindy has written about Humans.
Connection Strength

0.393
  1. Effects of GrandFusion Diet on Cognitive Impairment in Transgenic Mouse Model of Alzheimer's Disease. Nutrients. 2020 Dec 30; 13(1).
    View in: PubMed
    Score: 0.028
  2. GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
    View in: PubMed
    Score: 0.024
  3. Impact of nutrition on inflammation, tauopathy, and behavioral outcomes from chronic traumatic encephalopathy. J Neuroinflammation. 2018 Sep 24; 15(1):277.
    View in: PubMed
    Score: 0.024
  4. Preface. Turk J Med Sci. 2015; 45(5):i-ii.
    View in: PubMed
    Score: 0.018
  5. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
    View in: PubMed
    Score: 0.015
  6. Transcranial laser therapy attenuates amyloid-? peptide neuropathology in amyloid-? protein precursor transgenic mice. J Alzheimers Dis. 2011; 23(3):521-35.
    View in: PubMed
    Score: 0.014
  7. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of A?PP transgenic mice. J Alzheimers Dis. 2011; 25(2):295-307.
    View in: PubMed
    Score: 0.014
  8. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
    View in: PubMed
    Score: 0.014
  9. The impact of methylmercury on 1,25-dihydroxyvitamin D3-induced transcriptomic responses in dolphin skin cells. Biol Chem. 2010 Feb-Mar; 391(2-3):245-258.
    View in: PubMed
    Score: 0.013
  10. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008 May; 172(5):1342-54.
    View in: PubMed
    Score: 0.012
  11. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
    View in: PubMed
    Score: 0.011
  12. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res. 2007 Jun 04; 1152:191-200.
    View in: PubMed
    Score: 0.011
  13. Time window of fibroblast growth factor-18-mediated neuroprotection after occlusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab. 2004 Jan; 24(1):114-23.
    View in: PubMed
    Score: 0.009
  14. Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. Pharmacol Rev. 2022 07; 74(3):600-629.
    View in: PubMed
    Score: 0.008
  15. Exogenous Ketone Supplements Improved Motor Performance in Preclinical Rodent Models. Nutrients. 2020 Aug 15; 12(8).
    View in: PubMed
    Score: 0.007
  16. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000 Jun; 6(6):643-51.
    View in: PubMed
    Score: 0.007
  17. CBF regulation in hypertension and Alzheimer's disease. Clin Exp Hypertens. 2020 Oct 02; 42(7):622-639.
    View in: PubMed
    Score: 0.007
  18. Oxidized high-density lipoprotein induces neuron death. Exp Neurol. 2000 Feb; 161(2):621-30.
    View in: PubMed
    Score: 0.007
  19. Insights image for vitamin D binding protein polymorphisms significantly impact vitamin D status in children. Pediatr Res. 2019 11; 86(5):674.
    View in: PubMed
    Score: 0.006
  20. Vitamin D binding protein polymorphisms significantly impact vitamin D status in children. Pediatr Res. 2019 11; 86(5):662-669.
    View in: PubMed
    Score: 0.006
  21. Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes. PLoS One. 2018; 13(9):e0203460.
    View in: PubMed
    Score: 0.006
  22. Commentary: Addressing Racial Disparities in Stroke: The Wide Spectrum Investigation of Stroke Outcome Disparities on Multiple Levels (WISSDOM). Ethn Dis. 2018; 28(1):61-68.
    View in: PubMed
    Score: 0.006
  23. Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms. Prog Neurobiol. 2018 Jun - Aug; 165-167:26-50.
    View in: PubMed
    Score: 0.006
  24. Multi-Parametric Classification of Vascular Cognitive Impairment and Dementia: The Impact of Diverse Cerebrovascular Injury Biomarkers. J Alzheimers Dis. 2018; 62(1):39-60.
    View in: PubMed
    Score: 0.006
  25. Albumin-Assisted Method Allows Assessment of Release of Hydrophobic Drugs From Nanocarriers. Biotechnol J. 2018 Jan; 13(1).
    View in: PubMed
    Score: 0.006
  26. The Fli-1 transcription factor is a critical regulator for controlling the expression of chemokine C-X-C motif ligand 2 (CXCL2). Mol Immunol. 2017 01; 81:59-66.
    View in: PubMed
    Score: 0.005
  27. Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family. Genomics. 1996 May 15; 34(1):139-42.
    View in: PubMed
    Score: 0.005
  28. Non-genomic oestrogen receptor signal in B lymphocytes: An approach towards therapeutic interventions for infection, autoimmunity and cancer. Int J Biochem Cell Biol. 2016 07; 76:115-8.
    View in: PubMed
    Score: 0.005
  29. SIRT3 Deacetylates Ceramide Synthases: IMPLICATIONS FOR MITOCHONDRIAL DYSFUNCTION AND BRAIN INJURY. J Biol Chem. 2016 Jan 22; 291(4):1957-1973.
    View in: PubMed
    Score: 0.005
  30. Estrogen receptor signal in regulation of B cell activation during diverse immune responses. Int J Biochem Cell Biol. 2015 Nov; 68:42-7.
    View in: PubMed
    Score: 0.005
  31. 3D printing facilitated scaffold-free tissue unit fabrication. Biofabrication. 2014 Jun; 6(2):024111.
    View in: PubMed
    Score: 0.004
  32. Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury. J Biol Chem. 2014 May 09; 289(19):13142-54.
    View in: PubMed
    Score: 0.004
  33. Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis? J Neurotrauma. 2014 Feb 01; 31(3):215-27.
    View in: PubMed
    Score: 0.004
  34. Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
    View in: PubMed
    Score: 0.004
  35. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013 Jul; 136:233-7.
    View in: PubMed
    Score: 0.004
  36. Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. Am J Clin Nutr. 2012 Aug; 96(2):332-6.
    View in: PubMed
    Score: 0.004
  37. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.004
  38. Spinal cord infarction associated with subarachnoid hemorrhage. Clin Neurol Neurosurg. 2012 Sep; 114(7):1030-2.
    View in: PubMed
    Score: 0.004
  39. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
    View in: PubMed
    Score: 0.004
  40. Decompressive craniectomy: technical note. Acta Neurol Scand. 2011 Apr; 123(4):239-44.
    View in: PubMed
    Score: 0.004
  41. Targets for AD treatment: conflicting messages from ?-secretase inhibitors. J Neurochem. 2011 May; 117(3):359-74.
    View in: PubMed
    Score: 0.004
  42. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
    View in: PubMed
    Score: 0.003
  43. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009 Jan 27; 106(4):1285-90.
    View in: PubMed
    Score: 0.003
  44. Semi-allogeneic vaccines and tumor-induced immune tolerance. J Transl Med. 2009 Jan 08; 7:3.
    View in: PubMed
    Score: 0.003
  45. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
    View in: PubMed
    Score: 0.003
  46. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005 Feb 01; 14(3):447-60.
    View in: PubMed
    Score: 0.002
  47. Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets. 2004 Aug; 5(6):517-28.
    View in: PubMed
    Score: 0.002
  48. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system. Nucleic Acids Res. 2003 Nov 15; 31(22):6428-34.
    View in: PubMed
    Score: 0.002
  49. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003 Jul; 9(7):907-13.
    View in: PubMed
    Score: 0.002
  50. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003 Mar 15; 23(6):1992-6.
    View in: PubMed
    Score: 0.002
  51. Overexpression of SR-BI by adenoviral vector promotes clearance of apoA-I, but not apoB, in human apoB transgenic mice. J Lipid Res. 2002 Sep; 43(9):1421-8.
    View in: PubMed
    Score: 0.002
  52. Abeta deposition is essential to AD neuropathology. J Alzheimers Dis. 2002 Jun; 4(3):133-8.
    View in: PubMed
    Score: 0.002
  53. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002 Jun; 4(3):145-54.
    View in: PubMed
    Score: 0.002
  54. Key signaling pathways regulate the biological activities and accumulation of amyloid-beta. Neurobiol Aging. 2001 Nov-Dec; 22(6):967-73.
    View in: PubMed
    Score: 0.002
  55. Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radic Biol Med. 2001 Jul 01; 31(1):73-81.
    View in: PubMed
    Score: 0.002
  56. Differences in functional magnetic resonance imaging activation by category in a visual confrontation naming task. J Neuroimaging. 2001 Apr; 11(2):165-70.
    View in: PubMed
    Score: 0.002
  57. ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and glutamate transport and exacerbates ischemic brain injury. J Cereb Blood Flow Metab. 2000 Mar; 20(3):463-8.
    View in: PubMed
    Score: 0.002
  58. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology. 1999 Oct 22; 53(7):1391-6.
    View in: PubMed
    Score: 0.002
  59. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998 Jan 15; 18(2):687-97.
    View in: PubMed
    Score: 0.001
  60. Adenoviral vector-mediated overexpression of serum amyloid A in apoA-I-deficient mice. J Lipid Res. 1997 Aug; 38(8):1583-90.
    View in: PubMed
    Score: 0.001
  61. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24; 226(3):672-80.
    View in: PubMed
    Score: 0.001
  62. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995 May; 36(5):1058-65.
    View in: PubMed
    Score: 0.001
  63. Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J Lipid Res. 1995 Mar; 36(3):526-34.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.